Pictet Asset Management Holding SA Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Pictet Asset Management Holding SA grew its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 21.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,248,721 shares of the company's stock after purchasing an additional 223,384 shares during the quarter. Pictet Asset Management Holding SA owned approximately 1.58% of Viridian Therapeutics worth $23,938,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Viridian Therapeutics during the 3rd quarter worth approximately $208,000. Intech Investment Management LLC bought a new position in shares of Viridian Therapeutics during the third quarter valued at $422,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Viridian Therapeutics by 6.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 516,213 shares of the company's stock worth $11,744,000 after purchasing an additional 32,292 shares during the period. FMR LLC grew its stake in shares of Viridian Therapeutics by 16.8% in the third quarter. FMR LLC now owns 11,183,478 shares of the company's stock worth $254,424,000 after purchasing an additional 1,610,130 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock valued at $318,000 after purchasing an additional 2,036 shares during the period.

Remove Ads

Analyst Ratings Changes

Several research analysts have commented on the company. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Royal Bank of Canada lifted their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 17th. Needham & Company LLC reissued a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Finally, HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.70.

Viridian Therapeutics Stock Down 5.2 %

NASDAQ VRDN traded down $0.66 on Friday, hitting $11.99. 1,938,737 shares of the company were exchanged, compared to its average volume of 1,182,396. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a market cap of $977.01 million, a PE ratio of -2.78 and a beta of 0.81. The stock has a fifty day moving average of $16.18 and a 200-day moving average of $19.42. Viridian Therapeutics, Inc. has a 12 month low of $11.31 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. As a group, analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.